344 related articles for article (PubMed ID: 25572747)
21. Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years.
Farkas H; Kőhalmi KV
Expert Rev Clin Immunol; 2018 Jun; 14(6):447-460. PubMed ID: 29757016
[TBL] [Abstract][Full Text] [Related]
22. Characterization of patients with angioedema without wheals: the importance of F12 gene screening.
Firinu D; Bafunno V; Vecchione G; Barca MP; Manconi PE; Santacroce R; Margaglione M; Del Giacco SR
Clin Immunol; 2015 Apr; 157(2):239-48. PubMed ID: 25744496
[TBL] [Abstract][Full Text] [Related]
23. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
Wu MA; Zanichelli A; Mansi M; Cicardi M
Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema.
Wang Y; Jomphe C; Marier JF; Martin P
J Clin Pharmacol; 2021 Apr; 61(4):555-564. PubMed ID: 33091166
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
[TBL] [Abstract][Full Text] [Related]
26. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.
Greve J; Hoffmann TK; Schuler P; Lang S; Chaker A; Bas M
Int J Dermatol; 2011 Oct; 50(10):1294-5. PubMed ID: 21950301
[TBL] [Abstract][Full Text] [Related]
27. Nanofiltrated C1-esterase-inhibitor in the prophylactic treatment of bradykinin-mediated angioedema.
Greve J; Hahn J; Nordmann M; Schuler PJ; Bas M; Hoffmann TK; Hajdu Z; Buchberger M; Strassen U
Transfusion; 2016 May; 56(5):1022-9. PubMed ID: 26756974
[TBL] [Abstract][Full Text] [Related]
28. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
[TBL] [Abstract][Full Text] [Related]
29. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.
Guo Y; Zhang H; Lai H; Wang H; Chong-Neto HJ; Valle SOR; Zhu R
Orphanet J Rare Dis; 2022 Nov; 17(1):399. PubMed ID: 36324138
[TBL] [Abstract][Full Text] [Related]
30. Treatment with icatibant in the management of drug induced angioedema.
Bertazzoni G; Bresciani E; Cipollone L; Fante E; Galandrini R
Eur Rev Med Pharmacol Sci; 2015 Jan; 19(1):149-53. PubMed ID: 25635988
[TBL] [Abstract][Full Text] [Related]
31. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
Bork K
Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
[TBL] [Abstract][Full Text] [Related]
32. Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema.
Caballero T; Maurer M; Longhurst HJ; Aberer W; Bouillet L; Fabien V;
J Investig Allergol Clin Immunol; 2016; 26(6):383-386. PubMed ID: 27996949
[No Abstract] [Full Text] [Related]
33. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
Lumry WR; Li HH; Levy RJ; Potter PC; Farkas H; Moldovan D; Riedl M; Li H; Craig T; Bloom BJ; Reshef A
Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
[TBL] [Abstract][Full Text] [Related]
34. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.
Straka BT; Ramirez CE; Byrd JB; Stone E; Woodard-Grice A; Nian H; Yu C; Banerji A; Brown NJ
J Allergy Clin Immunol; 2017 Jul; 140(1):242-248.e2. PubMed ID: 27913306
[TBL] [Abstract][Full Text] [Related]
35. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
Riedl M
Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
[TBL] [Abstract][Full Text] [Related]
36. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.
Malbrán A; Riedl M; Ritchie B; Smith WB; Yang W; Banerji A; Hébert J; Gleich GJ; Hurewitz D; Jacobson KW; Bernstein JA; Khan DA; Kirkpatrick CH; Resnick D; Li H; Fernández Romero DS; Lumry W
Clin Exp Immunol; 2014 Aug; 177(2):544-53. PubMed ID: 24749847
[TBL] [Abstract][Full Text] [Related]
37. Icatibant for the treatment of hereditary angioedema.
Cole SW; Lundquist LM
Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
39. Management and prevention of hereditary angioedema attacks.
Lumry WR
Am J Manag Care; 2013 Jun; 19(7 Suppl):s111-8. PubMed ID: 23844783
[TBL] [Abstract][Full Text] [Related]
40. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
Maurer M; Aberer W; Caballero T; Bouillet L; Grumach AS; Botha J; Andresen I; Longhurst HJ;
Clin Exp Allergy; 2022 Sep; 52(9):1048-1058. PubMed ID: 35861129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
